WO2019035630A3 - 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 - Google Patents

인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 Download PDF

Info

Publication number
WO2019035630A3
WO2019035630A3 PCT/KR2018/009317 KR2018009317W WO2019035630A3 WO 2019035630 A3 WO2019035630 A3 WO 2019035630A3 KR 2018009317 W KR2018009317 W KR 2018009317W WO 2019035630 A3 WO2019035630 A3 WO 2019035630A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
fragment
present
cancer
growth factor
Prior art date
Application number
PCT/KR2018/009317
Other languages
English (en)
French (fr)
Other versions
WO2019035630A2 (ko
Inventor
남도현
박현규
Original Assignee
사회복지법인 삼성생명공익재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사회복지법인 삼성생명공익재단 filed Critical 사회복지법인 삼성생명공익재단
Publication of WO2019035630A2 publication Critical patent/WO2019035630A2/ko
Publication of WO2019035630A3 publication Critical patent/WO2019035630A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 인간 상피 성장 인자 수용체 변이체 Ⅲ에 결합하는 항체 및 그의 항체 단편에 관한 것이다. 본 발명에 따른 항체 및 그의 항체 단편은 EGFR에 대한 결합을 최소화하고, EGFRvⅢ만 특이적으로 인지하는 특징을 가진다. EGFRvⅢ는 고도로 암 특이적 항원이므로 본 발명에서 개발된 항체 및 항체단편은 암 조기 진단, 예방 및 치료에 적용이 가능하다. 또한 고도의 암특이성을 바탕으로 항체 또는 항체단편에 약물이나 T cell을 결합한 Antibody-Drug Conjugates(ADC)나 Chimeric Antigen Receptor-T(CAR-T) 기술을 적용하여 치료효능의 극대화가 가능하며, 정상세포에 발생 가능한 독성을 최소화 할 수 있다. 본 발명에 따른 항체 또는 항체단편에 직접 방사성동위원소나 형광물질을 결합하여 이미징하는 방법 또는 ELISA나 IHC법을 통해 EGFRvⅢ 돌연변이의 조기진단이 가능하다.
PCT/KR2018/009317 2017-08-14 2018-08-14 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 WO2019035630A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0103217 2017-08-14
KR20170103217 2017-08-14

Publications (2)

Publication Number Publication Date
WO2019035630A2 WO2019035630A2 (ko) 2019-02-21
WO2019035630A3 true WO2019035630A3 (ko) 2019-05-09

Family

ID=65362589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009317 WO2019035630A2 (ko) 2017-08-14 2018-08-14 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편

Country Status (2)

Country Link
KR (1) KR102119783B1 (ko)
WO (1) WO2019035630A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010119A1 (ko) * 2022-07-07 2024-01-11 주식회사 유틸렉스 돌연변이 egfr 및 epha2를 동시 타겟하는 키메라 항원 수용체

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222059A1 (en) * 2002-02-25 2005-10-06 Tang Careen K Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer
US20120189630A1 (en) * 2010-12-03 2012-07-26 Duke University BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
KR20120098932A (ko) * 2003-06-27 2012-09-05 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
KR20160131026A (ko) * 2014-03-11 2016-11-15 리제너론 파마슈티칼스 인코포레이티드 항-egfrviii 항체 및 그것의 용도
KR20170087439A (ko) * 2017-07-19 2017-07-28 주식회사 파멥신 신규 EGFRvlll 항체 및 이를 포함하는 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US10669340B2 (en) * 2016-02-15 2020-06-02 Samsung Life Public Welfare Foundation Antibody against EGFRvIII and use thereof
KR101953299B1 (ko) * 2018-08-02 2019-02-28 의료법인 성광의료재단 EGFRvIII에 대한 항체 및 이의 이용

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222059A1 (en) * 2002-02-25 2005-10-06 Tang Careen K Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer
KR20120098932A (ko) * 2003-06-27 2012-09-05 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
US20120189630A1 (en) * 2010-12-03 2012-07-26 Duke University BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
KR20160131026A (ko) * 2014-03-11 2016-11-15 리제너론 파마슈티칼스 인코포레이티드 항-egfrviii 항체 및 그것의 용도
KR20170087439A (ko) * 2017-07-19 2017-07-28 주식회사 파멥신 신규 EGFRvlll 항체 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
KR20190018399A (ko) 2019-02-22
KR102119783B1 (ko) 2020-06-08
WO2019035630A2 (ko) 2019-02-21

Similar Documents

Publication Publication Date Title
AU2018263862A1 (en) Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
MX2021014094A (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
WO2015200828A8 (en) Conjugates for immunotherapy
EP3539988A3 (en) Monoclonal antibodies against her2
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MY194997A (en) Anti-ccr7 antibody drug conjugates
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
EA201490974A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
UA106890C2 (uk) Гуманізоване антитіло до cdcp1
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
WO2012079878A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2019009121A (es) Antcuerpos anti-kaag1 o fragmento de union al antigeno del mismo para el tratamiento de cancer de mama triple negativo.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18846628

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18846628

Country of ref document: EP

Kind code of ref document: A2